Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.

New treatments for a type of skin cancer show promise but have side effects and may work better with other therapies.

Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.

JAK inhibitors show promise for treating various skin diseases.

Keratinocytes can reduce the survival of certain melanoma cells, suggesting new therapy paths.

Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.

CTHRC1 helps sweat glands recover by rebuilding nearby blood vessels.

Ruxolitinib cream effectively targets and treats inflammatory skin diseases.

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.

Cadd4 effectively reduces cholesterol levels without side effects.

Lower SMAD2/3 activation predicts more severe skin cancer.

Changing the C-ring structure in certain compounds can make them better at blocking a specific human enzyme.

Connexin-26 gene mutations may increase cancer risk in KID syndrome patients.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

EGCG may help regrow hair by inhibiting a specific enzyme.

Granulocyte colony stimulating factor helps heal wounds without scars.

ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.

DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.

CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.

CYLD deficiency in skin tumors disrupts hair follicle cell processes and protein secretion.

The microenvironment affects the behavior and survival of melanocytes with the GNAQ oncogene in melanoma.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

Vaccines and targeting TrxR variants can help prevent cancer and reduce metastasis.

Bedaquiline, Telmisartan, Diosmin, Azelastine, and Adapalene may be effective treatments for onchocerciasis.

HPH-15, a new compound, effectively reduces skin fibrosis in experiments without causing harm.

The conclusion is that a new test was created to find substances that affect specific ion channels, and it works well for drug discovery.

GBP1 is a key target for treating Epstein-Barr virus-related kidney cancer, and finasteride may help.

AP-1 and TGFß work together to drive resistance in basal cell carcinoma, suggesting new treatment options.